Salute e Benessere
mAIbe and LenioBio announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies
LenioBio's ultrafast, scalable expression system enables rapid production of complex antibodies, providing high-quality experimental data that feeds directly into mAIbe's AI models.
Through this integrated approach, the two teams will jointly:
Together, mAIbe and LenioBio set a new standard for speed, flexibility, and data-driven innovation in therapeutic antibody discovery by closing the lab-in-loop gap.
LenioBio GmbH is a biotechnology company pioneering cell-free protein expression with its ALiCE® platform, enabling rapid discovery, development, and scalable production of proteins beyond the limits of living cells. Founded in
Germany in 2016, LenioBio is headquartered in Düsseldorf with R&D and manufacturing facilities in Aachen. Learn more at www.leniobio.com and follow LenioBio on LinkedIn.
mAIbe is a biotechnology company focused on AI-guided monoclonal antibody design. Its platform combines physics-informed generative AI and synthetic biology to develop precise, cost-effective antibodies targeting viral and bacterial pathogens. Based in Rome, Italy , mAIbe operates at the convergence of artificial intelligence and life sciences to accelerate the development of accessible, next-generation immunotherapies. Learn more at: www.maibe.eu
Akanksha Ranjit
Marketing & Communications
LenioBio GmbH
a.ranjit@leniobio.com
Logo - https://mma.prnewswire.com/media/2735875/5641774/LenioBio_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/maibe-and-leniobio-announce-a-new-strategic-collaboration-aimed-at-accelerating-the-discovery-and-experimental-validation-of-next-generation-monoclonal-antibodies-302625977.html